World Health Organization experts provide guidance on use of the Oxford vaccine

Report of a one-day convening on regulatory science, practices, and innovative approaches to facilitate approval of novel combination vaccines.

Hausdorff WP. et al, (2026), Vaccine, 75

The Epidemiology and Clinical Burden of Human Adenovirus Respiratory Infections Among Hospitalized Children Under 5 Years in Jordan.

Abu-Helalah M. et al, (2026), Pediatr Infect Dis J, 45, 229 - 235

Severe necrotizing soft tissue infections (SENSEI) study: Protocol for a multi-centered audit.

Yoshimura R. et al, (2026), JPRAS Open, 48, 331 - 336

Securing the future of immunisation: ESCMID’s vision

Ramasamy MN. et al, (2026), CMI Communications, 3, 105167 - 105167

Maternal perspectives on the RSV vaccine (Abrysvo): a thematic analysis of survey findings from the first season of implementation in England and Scotland.

O'Hagan S. et al, (2026), Arch Dis Child

Pooled analysis of PCV13 efficacy from controlled human infection trials in Malawi and the UK.

Kudowa E. et al, (2026), NPJ Vaccines

n Adenoviral Vectored Vaccine Protects Mice Against Aerosol Challenge with Yersinia pestis.

Dold C. et al, (2026), Mol Ther

Predicting Salmonella Typhi incidence using prevalence metrics from sentinel studies of community-onset bloodstream infections

Hagedoorn N. et al, (2026)

Controlled human pneumococcal infection in the Netherlands: Colonisation, antibody responses and the impact of viral co-infection.

van Beek LF. et al, (2026), J Infect, 92

Enablers and barriers to participation in vaccine trials: a narrative synthesis.

Daniel N. et al, (2026), Vaccine, 73

Maternal iron status and total immunoglobulin-G influence transplacental antibody transfer across eight diverse geographical settings.

Tiley KS. et al, (2026), Vaccine, 73

The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trial.

Liatsikos K. et al, (2026), Lancet Microbe

isk to child health: confusion and concern over changes to US vaccine policy.

Pollard AJ. and Plotkin S., (2026), Lancet, 407, 553 - 556

Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.

Turkalj S. et al, (2026), Blood, 147, 613 - 632

SARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study.

Brugha R. et al, (2026), J Pediatr, 289

En-risk to de-risk: An iterative human factors framework for scale development in emerging technologies.

Kantor J. et al, (2026), JAAD Int, 24, 342 - 345

Machine learning-driven identification of serotype-independent pneumococcal vaccine candidates using samples from human infection challenge studies.

Cheliotis KS. et al, (2026), Vaccine, 75

Causes of Fever in a Cohort of Nepali Children and the Potential Impact of Molecular Testing During a Dengue Fever Outbreak.

O'Reilly PJ. et al, (2026), Pediatr Infect Dis J

Maternal views on RSV vaccination in the UK's second season.

O'Hagan S. et al, (2026), Lancet Infect Dis

Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against Salmonella Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocol.

Paganotti Vicentine M. et al, (2026), BMJ Open, 16

Search results

Showing results for